Kamekura Ryuta

カメクラリュウタ | Kamekura Ryuta

Affiliation and department：
Job title： -

Research field (2)： Otorhinolaryngology , Immunology

Research keywords (4)： epimmunome , epithelial cells , タイト結合 , 鼻咽腔粘膜上皮バリア機能

Research theme for competitive and other funds (19)：

2024 - 2027 ダニ特異的SLITにおけるT濾胞ヘルパー細胞及び免疫記憶と免疫疲労の解析
2024 - 2027 IgG4関連疾患の解析に基づいたヒトIgEのクラススイッチの制御機構の解明
2022 - 2026 T 細胞疲弊を標的としたアレルギー性鼻炎の新規治療戦略
2021 - 2024 The analysis of T follicular helper and regulatory cells of patients with atopic asthma comorbid with allergic rhinitis by treated with HDM-SLIT
2021 - 2024 唾液腺免疫性疾患における腺機能障害に対する基礎的研究

Show all

Papers (72)：

Taiki Sato, Ippei Ikegami, Masahiro Yanagi, Takeshi Ohyu, Taiki Sugaya, Shotaro Shirato, Masanobu Tanemoto, Shiori Kamiya, Kohei Kikuchi, Yuka Kamada, et al. Interleukin 9 mediates T follicular helper cell activation to promote antibody responses. Frontiers in Immunology. 2024. 15
Masahiro Yanagi, Ippei Ikegami, Ryuta Kamekura, Tatsuya Sato, Taiki Sato, Shiori Kamiya, Kosuke Murayama, Sumito Jitsukawa, Fumie Ito, Akira Yorozu, et al. Bob1 maintains T follicular helper cells for long-term humoral immunity. Communications biology. 2024. 7. 1. 185-185
Katsunori Shigehara, Ryuta Kamekura, Ippei Ikegami, Hiroshi Sakamoto, Masahiro Yanagi, Shiori Kamiya, Kentaro Kodama, Yuichiro Asai, Satsuki Miyajima, Hirotaka Nishikiori, et al. Circulating T follicular helper 2 cells, T follicular regulatory cells and regulatory B cells are effective biomarkers for predicting the response to house dust mite sublingual immunotherapy in patients with allergic respiratory diseases. Frontiers in Immunology. 2023. 14
亀倉隆太, 重原克則, 山本圭佑, 一宮慎吾, 高野賢一. 通年性アレルギー性鼻炎・各種鼻炎:治療・管理・診断ダニ舌下免疫療法の新しい効果発現のメカニズムの解明. アレルギー. 2023. 72. 6-7. 872-872
重原克則, 亀倉隆太, 宮島さつき, 小玉賢太郎, 錦織博貴, 千葉弘文. 免疫療法・薬物療法(臨床) 鼻炎合併喘息患者におけるダニ舌下免疫療法のICS減量効果 3年間の解析. アレルギー. 2023. 72. 6-7. 882-882

ｍore...

MISC (32)：

ｍore...

Professional career (1)：

医学博士 (札幌医科大学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page